Teladoc Health (NYSE:TDOC) Insider Sells $47,275.48 in Stock

Teladoc Health, Inc. (NYSE:TDOC) insider Carlos Nueno sold 6,196 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider directly owned 57,671 shares of the company’s stock, valued at $440,029.73. This represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Stock Down 3.6%

Shares of NYSE TDOC opened at $7.05 on Friday. Teladoc Health, Inc. has a 52-week low of $4.40 and a 52-week high of $9.77. The firm has a fifty day moving average of $6.20 and a 200-day moving average of $6.22. The stock has a market capitalization of $1.27 billion, a PE ratio of -7.26 and a beta of 2.14. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $613.85 million for the quarter, compared to analysts’ expectations of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm’s quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, analysts anticipate that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Hedge Funds Weigh In On Teladoc Health

Institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc lifted its holdings in Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after buying an additional 2,810 shares in the last quarter. Aster Capital Management DIFC Ltd lifted its holdings in Teladoc Health by 101.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock worth $37,000 after buying an additional 2,425 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Teladoc Health by 694.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after buying an additional 4,945 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in Teladoc Health in the 4th quarter worth $45,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TDOC shares. Citigroup lifted their target price on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Barclays reduced their target price on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Oppenheimer reduced their target price on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, March 3rd. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Thursday, February 26th. Finally, Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.43.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.